IDEAYA Biosciences, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $218.7M | $7.0M | $23.4M | $50.9M | $27.9M | $19.5M | $0 |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | $314.7M | $294.7M | $129.5M | $89.5M | $58.2M | $39.7M | $34.3M |
| SG&A Expense | $63.3M | $39.3M | $28.3M | $23.9M | $20.1M | $15.2M | $10.0M |
| Operating Income | $-159.3M | $-327.0M | $-134.4M | $-62.5M | $-50.3M | $-35.3M | $-44.3M |
| Operating Margin | -72.8% | -4,671.1% | -574.9% | -122.7% | -179.9% | -180.9% | — |
| Interest Expense | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-113.7M | $-274.5M | $-113.0M | $-58.7M | $-49.8M | $-34.5M | $-42.0M |
| Net Margin | -52.0% | -3,921.1% | -483.0% | -115.2% | -178.1% | -176.6% | — |
| EPS (Basic) | $-1.28 | $-3.36 | $-1.96 | $-1.42 | $-1.41 | $-1.40 | $-3.36 |
| EPS (Diluted) | $-1.28 | $-3.36 | $-1.96 | $-1.42 | $-1.41 | $-1.40 | $-3.36 |
| Shares Outstanding (Basic) | 88.5M | 81.7M | 57.5M | 41.4M | 35.3M | 24.7M | 20.3M |
| Shares Outstanding (Diluted) | 88.5M | 81.7M | 57.5M | 41.4M | 35.3M | 24.7M | 20.3M |
| Dividends Per Share | — | — | — | — | — | — | — |